Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Drugs
Published in: Drugs 5/2001

01-04-2001 | Adis New Drug Profile

Levosimendan

A Viewpoint by Markku S. Nieminen

Author: Markku S. Nieminen

Published in: Drugs | Issue 5/2001

Login to get access

Excerpt

Calcium sensitising has been proposed as the best way to improve deteriorating cardiac cell function in heart failure. However, it has proven difficult to develop agents which have a safe mode of action. To date, most agents evaluated in clinical trials also possess phosphodiesterase III and IV inhibitory activity, which may account for their adverse effects. …
Metadata
Title
Levosimendan
A Viewpoint by Markku S. Nieminen
Author
Markku S. Nieminen
Publication date
01-04-2001
Publisher
Springer International Publishing
Published in
Drugs / Issue 5/2001
Print ISSN: 0012-6667
Electronic ISSN: 1179-1950
DOI
https://doi.org/10.2165/00003495-200161050-00008

Other articles of this Issue 5/2001

Drugs 5/2001 Go to the issue

Adis New Drug Profile

Bendamustine

Adis New Drug Profile

Levosimendan

Therapy in Practice

Achieving Optimal Outcomes in Chronic Lymphocytic Leukaemia

Review Article

Topical Corticosteroids in Nasal Polyposis

Adis Drug Evaluation

Risedronate

Leading Article

Vaccines Without Thiomersal